Discovery of INT131: A selective PPARI3 modulator that enhances insulin sensitivity

PPARI3 is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPARI3 modulators (SPPARI3Ms) and display a unique pharma...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2013-02, Vol.21 (4), p.979-992
Main Authors: Taygerly, Joshua, McGee, Lawrence, Rubenstein, Steven, Houze, Jonathan, Cushing, Timothy, Li, Yang, Motani, Alykhan, Chen, Jin-Long, Frankmoelle, Walter, Ye, Guosen, Learned, Marc, Jaen, Juan, Miao, Shichang, Timmermans, Pieter, Thoolen, Martin, Kearney, Patrick, Flygare, John, Beckmann, Holger, Weiszmann, Jennifer, Lindstrom, Michelle, Walker, Nigel, Liu, Jinsong, Biermann, Donna, Wang, Zhulun, Hagiwara, Atsushi, Iida, Tetsuya, Aramaki, Hisateru, Kitao, Yuki, Shinkai, Hisashi, Furukawa, Noboru, Nishiu, Jun, Nakamura, Motonao
Format: Article
Language:English
Subjects:
Diabetes mellitus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PPARI3 is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPARI3 modulators (SPPARI3Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPARI3 full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPARI3 partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.
ISSN:0968-0896
DOI:10.1016/j.bmc.2012.11.058